<DOC>
	<DOC>NCT03037372</DOC>
	<brief_summary>This study will determine whether 36 months of daily atorvastatin or rosuvastatin have equivalent effects in reduction of immune activation, inflammation and immune aging, when given as adjunct therapy among patients receiving antiretroviral therapy in an African cohort</brief_summary>
	<brief_title>Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence Trial</brief_title>
	<detailed_description>This is a randomized, open-label trial</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>HIVpositive individuals 18 years and older, that have initiated three firstline drug highly active antiretroviral therapy within three months within the Infectious Diseases Institute HIV treatment cohort Individuals that provide written informed consent to participate in the clinical trial Individuals with dyslipidemia and eligible to receive or already receiving statin therapy Pregnant or lactating mothers Individuals with another active or controlled inflammatory condition Individuals with deranged liver function tests 3 fold and above</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>adults</keyword>
	<keyword>antiretroviral therapy</keyword>
</DOC>